Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Venmax Drugs & Pharmaceuticals Ltd (VENMAX) is currently trading at 24.49 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Venmax Drugs & Pharmaceuticals Limited (VDPL) is primarily engaged in pharmaceutical product manufacturing, focusing on drug intermediaries and APIs. Recently, the company has ventured into establishing a chain of medical stores under the 'Ananya Pharma' brand, supported by its formulations plant, Suzichem Labs. Originally established in 1998, VDPL has undergone several name changes, reflecting its evolving business strategy and market positioning. As part of its diversification, VDPL is also involved in IT and ITES services, indicating a strategic move to broaden its revenue streams.
Over the past 52 weeks, Venmax Drugs & Pharmaceuticals Ltd has traded between a low of ₹19.01 and a high of ₹36.96. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of approximately 20.60. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Venmax Drugs & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.20 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 20.60 Cr, Venmax Drugs & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Venmax Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Venmax Drugs & Pharmaceuticals Ltd is 22.20. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
4
Neutral
6
Bullish
4
Bearish
28
Neutral
6
Bullish
12
Bearish
24
Neutral
0
Bullish
8
Discovery themes featuring this stock
Venmax Drugs & Pharmaceuticals Limited (VDPL) is primarily engaged in pharmaceutical product manufacturing, focusing on drug intermediaries and APIs.
Recently, the company has ventured into establishing a chain of medical stores under the 'Ananya Pharma' brand, supported by its formulations plant, Suzichem Labs.
Originally established in 1998, VDPL has undergone several name changes, reflecting its evolving business strategy and market positioning.
As part of its diversification, VDPL is also involved in IT and ITES services, indicating a strategic move to broaden its revenue streams.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs
21 Cr
Low Risk
22.2
56.9
—
2.0
36.96
19.01
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
83.00 | 62 Cr | 16.90 | 1.44 | 0.00 | 12.65 | 11.11 | 2.27 | |
34.60 | 56 Cr | 5.53 | 0.94 | 0.00 | 13.52 | 17.90 | 12.26 | |
34.65 | 48 Cr | 216.56 | 2.10 | 0.00 | 1.08 | 3.59 | 1.00 | |
43.40 | 35 Cr | 17.79 | 1.94 | 0.00 | 10.56 | 10.48 | 2.23 | |
71.03 | 24 Cr | 23.92 | 2.14 | 0.00 | 8.65 | 10.56 | 6.11 | |
24.49 | 21 Cr | 22.20 | 2.03 | 0.00 | 4.02 | 3.11 | 6.37 | |
28.85 | 11 Cr | -2.13 | 0.00 | 0.00 | 75.76 | -46.38 | -28.70 |
